drugset / Trial / NCT01591122
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to demonstrate the safety and effectiveness of abiraterone acetate when co-administered with prednisone in patients with chemo-naive metastatic castration resistant prostate Cancer (mCRPC).
Timeline
- Start
- 2012-03-27
- Primary completion
- 2016-12-31
- Completion
- 2019-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | 250 mg | Oral |
| Comparator | Prednisone | Other / unclassified | 5 mg | Oral |